Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15068013 | 0.88 | TSHR (0.69) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL25312484 | 0.86 | MCOLN3 (0.50) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7210060 | 0.86 | LMNA (0.69) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL3300806 | 0.86 | TSHR (0.75) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL3024918 | 0.86 | HSD17B10 (0.61) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL29130948 | 0.86 | HSD17B10 (0.57) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL14501796 | 0.84 | HSD17B10 (0.60) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL16735251 | 0.83 | LMNA (0.62) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL711636 | 0.82 | ABL1 (0.71) | TSHRSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL24762031 | 0.82 | PKM (0.56) | TSHRSMN1; SMN2ALDH1A1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8513232-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513232-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| CN-101501035-B | Pyrimidine derivatives as PI3K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD | 2013-01-23 | — | — | CN | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| CN-101501035-A | Pyrimidine derivatives as P13K inhibitors and uses thereof | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | TSHR 324/4885SMN1; SMN2 4691/4885LMNA 4289/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | TSHR 3412/4885SMN1; SMN2 3098/4885LMNA 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.